Opthea Limited (NASDAQ:OPT - Get Free Report) traded up 1.7% on Friday . The stock traded as high as $4.18 and last traded at $4.11. 30,069 shares were traded during mid-day trading, an increase of 24% from the average session volume of 24,241 shares. The stock had previously closed at $4.04.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright decreased their target price on Opthea from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Tuesday, September 3rd.
Get Our Latest Stock Report on OPT
Opthea Stock Up 1.7 %
The company has a 50 day moving average of $4.09 and a 200 day moving average of $3.13.
Opthea Company Profile
(
Get Free Report)
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Read More
Before you consider Opthea, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opthea wasn't on the list.
While Opthea currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
